Literature DB >> 12648034

The economic burden of stroke in the United Kingdom.

Penny Youman1, Koo Wilson, Farzaneh Harraf, Lalit Kalra.   

Abstract

AIM: To estimate the cost of treating stroke in the UK.
METHODS: A cost-of-illness model was constructed to estimate stroke-related costs over a 5-year period. The cost estimates were based on data from a large, randomised, prospective study comparing alternative strategies of stroke care. The study collected detailed data on resource use in hospital, primary care, healthcare contacts, and utilisation of social services over a period of 1 year following stroke. A Markov framework was used to extrapolate 1-year costs over 5 years.
RESULTS: The model estimated that, for every patient who experiences a stroke, the cost to the NHS in the UK is pound 15306 over 5 years and, when informal care costs are included, the amount increases to pound 29405 (2001/2002 prices). The robustness of the cost findings was explored with the use of sensitivity analysis. This focused on the key variables of rates of recurrent stroke, the estimated acute costs, and costs attached to institution and home care.
CONCLUSION: As well as being a considerable cause of morbidity and mortality, stroke is also a huge cost burden to both the UK's NHS and the carers of stroke victims.

Entities:  

Mesh:

Year:  2003        PMID: 12648034     DOI: 10.2165/00019053-200321001-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  19 in total

1.  Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe.

Authors:  Lennart Hansson; Adam Lloyd; Pippa Anderson; Zoe Kopp
Journal:  Blood Press       Date:  2002       Impact factor: 2.835

2.  The national sentinel audit for stroke: a tool for raising standards of care.

Authors:  A G Rudd; P Irwin; Z Rutledge; D Lowe; D Wade; R Morris; M G Pearson
Journal:  J R Coll Physicians Lond       Date:  1999 Sep-Oct

3.  Costs and disability among stroke patients.

Authors:  S Kavanagh; M Knapp; A Patel
Journal:  J Public Health Med       Date:  1999-12

4.  Stroke treatment economic model (STEM): predicting long-term costs from functional status.

Authors:  J J Caro; K F Huybrechts
Journal:  Stroke       Date:  1999-12       Impact factor: 7.914

Review 5.  Diabetes in Canada: direct medical costs of major macrovascular complications.

Authors:  J A O'Brien; I Caro; D Getsios; J J Caro
Journal:  Value Health       Date:  2001 May-Jun       Impact factor: 5.725

6.  Alternative strategies for stroke care: a prospective randomised controlled trial.

Authors:  L Kalra; A Evans; I Perez; M Knapp; N Donaldson; C G Swift
Journal:  Lancet       Date:  2000-09-09       Impact factor: 79.321

Review 7.  Long term cost-of-illness in stroke: an international review.

Authors:  Krista A Payne; Krista F Huybrechts; J Jaime Caro; Traci J Craig Green; Wendy S Klittich
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

8.  Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project.

Authors:  J Burn; M Dennis; J Bamford; P Sandercock; D Wade; C Warlow
Journal:  Stroke       Date:  1994-02       Impact factor: 7.914

9.  Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.

Authors:  B F Gage; A B Cardinalli; G W Albers; D K Owens
Journal:  JAMA       Date:  1995-12-20       Impact factor: 56.272

Review 10.  Lifetime cost of stroke in the United States.

Authors:  T N Taylor; P H Davis; J C Torner; J Holmes; J W Meyer; M F Jacobson
Journal:  Stroke       Date:  1996-09       Impact factor: 7.914

View more
  37 in total

1.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

2.  The economic burden of atherothrombosis in Greece: results from the THESIS study.

Authors:  Nikos Maniadakis; Georgia Kourlaba; Dennis V Cokkinos; Aggeliki Angeli; John Kyriopoulos
Journal:  Eur J Health Econ       Date:  2012-07-10

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  Aneurysmal subarachnoid haemorrhage: guidance in making the correct diagnosis.

Authors:  W A Liebenberg; R Worth; G B Firth; J Olney; J S Norris
Journal:  Postgrad Med J       Date:  2005-07       Impact factor: 2.401

5.  Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review.

Authors:  Kirsty Winkley; Rebecca Upsher; Daniel Stahl; Daniel Pollard; Architaa Kasera; Alan Brennan; Simon Heller; Khalida Ismail
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

6.  Observation or operation for patients with an asymptomatic inguinal hernia: a randomized clinical trial.

Authors:  Patrick J O'Dwyer; John Norrie; Ahmed Alani; Andrew Walker; Felix Duffy; Paul Horgan
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

Review 7.  Alteplase for the treatment of acute ischaemic stroke: a NICE single technology appraisal; an evidence review group perspective.

Authors:  Michael Holmes; Sarah Davis; Emma Simpson
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

8.  The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.

Authors:  Patrick W Sullivan; Thomas W Arant; Samuel L Ellis; Heather Ulrich
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 9.  A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies.

Authors:  Ching-Yun Wei; Ruben G W Quek; Guillermo Villa; Shravanthi R Gandra; Carol A Forbes; Steve Ryder; Nigel Armstrong; Sohan Deshpande; Steven Duffy; Jos Kleijnen; Peter Lindgren
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

10.  The cost of materials for intra-arterial thrombectomy.

Authors:  F Bing; G Jacquin; A Poppe; D Roy; J Raymond; A Weill
Journal:  Interv Neuroradiol       Date:  2013-03-04       Impact factor: 1.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.